This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	Heparan sulfate 6- <i>O</i> -sulfotransferase 1 (HS6ST1); HS6ST2	<i>In vitro</i> and mouse studies suggest inhibiting HS6ST1 and HS6ST2 could help treat ovarian cancer. In human ovarian cancer cell lines, shRNA against HS6ST1 or HS6ST2 decreased epidermal growth factor receptor (EGFR) signaling and downstream expression of angiogenic cytokines compared with nonspecific shRNA. In mice with ovarian cancer, shRNA against HS6ST2 delayed and decreased tumor growth compared with nonspecific shRNA. Next steps include identifying biomarkers to predict response to drugs targeting angiogenic signaling pathways induced by heparan sulfate 6- <i>O</i> -sulfotransferases.	Unpatented; licensing status not applicable	Cole, C.L. <i>et al. J. Biol. Chem.</i> ; published online Feb. 22, 2014; doi:10.1074/jbc.M113.534263 Contact: Egle Avizienyte, The University of Manchester, Manchester, U.K. e-mail: egle.avizienyte@ics.manchester.ac.uk
SciBX 7(12); doi:10.1038/scibx.2014.342 Published online March 27, 2014				